secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001503274-25-000022
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix highlights Akoya acquisition benefits; responds to Kent Lake director nominations
--------------------------------------------------------------------------------

- Acquisition unlocks $5B addressable market in spatial biology and $10B Alzheimer's diagnostics opportunity.
- Expects ~$40M annual run-rate cost synergies by end of 2026, with $20M in the first year after close.
- Targets ~$1B revenue and ~15% EBIT margins within five years post-close; positive free cash flow expected in 2026.
- Kent Lake PR LLC nominated three director candidates for 2025 Annual Meeting; Quanterix criticizes assumptions as flawed.
- Transaction expected to close in Q2 2025, pending shareholder approvals and customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000150327425000022/0001503274-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000150327425000022/qtrx-20250303.htm
  HTML page:      https://secwatch.observer/filing/0001503274-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer